Presynaptic Dopamine in Schizophrenia
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Presynaptic dopamine (DA) transmission has been measured in schizophrenia using different paradigms aimed at providing estimates of the integrity or the activity of the presynaptic dopaminergic neuron. RESEARCHERS HAVE MEASURED: (1) DA synthesis capacity with [(18) F]DOPA, a measure of the activity of dopa decarboxylase, (2) DA release with studies measuring the impact of a DA releasing stimulant challenge on the binding of a D(2) receptor radiotracer, (3) D(2) baseline occupancy by DA, a measure of baseline intrasynaptic DA, assessed by the changes in binding of D(2) radiotracer induced by DA depletion, and (4) the DA and the vesicular monoamine transporters, to assess the integrity of presynaptic terminals. The relationship between DA release and D(2) receptor occupancy at baseline by DA has also been assessed in the same patients. Overall, these different imaging modalities have converged to show a dysregulation of presynaptic dopaminergic activity in schizophrenia, leading to excessive DA release in the striatum, particularly in the projection to the associative striatum, an area of integration between cognitive and limbic cortical inputs. Excessive striatal presynaptic DA is linked to the emergence of acute psychotic symptoms and to their response to treatment in schizophrenia. Understanding the etiology of this dysregulation and its consequences on the rest of the circuitry is important for future drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · cited 1×
“The correlation between clinical doses of antipsychotic drugs and their potency to block DA D2 receptors [3,4], as well as the observations of psychotogenic effects of DA enhancing drugs [for review, see Refs.”
BackgroundGrace, A. A. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90196-u · Cited by 1,831
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 1×
“With imaging, synaptic DA release in the striatum, measured as the change in D2 radiotracer binding potential after administration of the DA-releasing drug amphetamine, has been shown to be increased in schizophrenia [43–45] (Figure 1).”
BackgroundSelf-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“With imaging, synaptic DA release in the striatum, measured as the change in D2 radiotracer binding potential after administration of the DA-releasing drug amphetamine, has been shown to be increased in schizophrenia [43–45] (Figure 1).”
BackgroundIncreased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020 · cited 3×
“[49] found that the increase in D2 receptor availability after acute DA depletion was significantly larger in patients with schizophrenia compared to controls, indicating increased occupancy of striatal D2 receptors by DA at baseline in schizophrenia.”
BackgroundSelf-citationImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Elevated Striatal Dopamine Function Linked to Prodromal Signs of Schizophrenia
Howes, O. D., Montgomery, A. J., Asselin, M.-C., Murray, R. M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.514 · Cited by 744 · cited 1×
“[37] recently reported that striatal [18F]DOPA uptake was significantly increased among individuals experiencing prodromal symptoms of schizophrenia compared to controls, and that DOPA uptake correlated significantly with severity of prodromal symptoms.”
BackgroundReduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia
Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., Weinberger, D. R., & Berman, K. F. (2002) · Nature Neuroscience · doi:10.1038/nn804 · Cited by 652 · cited 1×
“[39] found that reduced activation in the DLPFC during an executive functioning task, as measured by PET with [(15)O]H2O, was associated with increased striatal DOPA uptake in patients but not controls, providing additional support for the relation between prefrontal dysfunction and potentiated striatal DA activity in…”
ResultMeyer-Lindenberg, A. S., Olsen, R. K., Kohn, P. D., Brown, T., Egan, M. F., Weinberger, D. R., & Berman, K. F. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.379 · Cited by 574 · cited 1×
“Hippocampal pathology is also present in patients with schizophrenia [66–68], suggesting that the hippocampus may play an essential role in the genesis of the dopaminergic pathology in schizophrenia.”
BackgroundImpaired recruitment of the hippocampus during conscious recollection in schizophrenia
Heckers, S., Rauch, S., Goff, D., Savage, C., Schacter, D., Fischman, A., & Alpert, N. (1998) · Nature Neuroscience · doi:10.1038/1137 · Cited by 570 · cited 1×
“Hippocampal pathology is also present in patients with schizophrenia [66–68], suggesting that the hippocampus may play an essential role in the genesis of the dopaminergic pathology in schizophrenia.”
Background
Cited by
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
Slifstein, M., van de Giessen, E., Van Snellenberg, J., Thompson, J. L., Narendran, R., Gil, R., Hackett, E., Girgis, R., Ojeil, N., Moore, H., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2414 · Cited by 398
Self-citationStriatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [18F/11C]-DOPA PET Studies
Fusar-Poli, P., & Meyer-Lindenberg, A. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr180 · Cited by 262
Extracellular matrix abnormalities in schizophrenia
Berretta, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.010 · Cited by 179
Clarke, H. F., Cardinal, R. N., Rygula, R., Hong, Y. T., Fryer, T. D., Sawiak, S. J., Ferrari, V., Cockcroft, G., Aigbirhio, F. I., Robbins, T. W., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0718-14.2014 · Cited by 54
Metadata
- Authors
- Miyake, N., Thompson, J., Skinbjerg, M., & Abi-Dargham, A.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2010-12-27
- Volume
- 17
- Issue
- 2
- Pages
- 104-109
- ISSN
- 1755-5930 (ISSN-L)
- OpenAlex
- W2116261431
- Cited by
- 52
- References
- 17
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Presynaptic Dopamine in Schizophrenia. https://app.cochat.ai/papers/10.1111/j.1755-5949.2010.00230.x
- The paper
- Miyake, N., Thompson, J., Skinbjerg, M., & Abi-Dargham, A. (2011). Presynaptic Dopamine in Schizophrenia. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/j.1755-5949.2010.00230.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.